LB Pharmaceuticals Inc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LBRX | BHVN | ATAI | B9A.F | ANRO | LXRX | |
|---|---|---|---|---|---|---|
| Market cap | 1.32B | 2.30B | — | 2.45B | 914.34M | 658.53M |
| P/E (TTM) | 408.5 | — | — | 250.7 | — | — |
| Forward P/E | -7.6 | -8.2 | — | — | -7.3 | -7.8 |
| Price/book | 3.5 | -23.4 | — | 1.2 | 3.7 | 3.8 |
| Dividend yield | — | — | — | 0.68% | — | — |
| 1-year change | +163.38% | +78.66% | — | +13.08% | +109.34% | +5.80% |
| Today | +1.29% | −2.37% | 0.00% | −0.29% | +2.64% | +1.37% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LBRX news ›Profund Advisors LLC Makes New $1.08 Million Investment in LB Pharmaceuticals Inc $LBRX
Posted by Sarita Garza on Nov 4th, 2026 Shares of NASDAQ LBRX opened at $40.33 on Wednesday. LB Pharmaceuticals Inc has a one year low of $14.32 and a one year high of $50.16. The firm’s 50 day simple moving average is $41.05 and its…
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payments totaling $350…
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at Wall Street Zen
Posted by Kim Johansen on Nov 3rd, 2026 Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) from a strong sell rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen…
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
Posted by Tristan Rich on Oct 30th, 2026 LB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D…
Nuode Asset, GF Securities, Caitong Fund Management, Shanghai Jinde Private Fund Management and Shanghai Muxin Private Fund Management agreed to acquire 2% stake in Guangzhou LBP Medicine Science & Technology Co., Ltd. from Hangzhou Gaotejia Ruihai, Chongqing Gaotejia Rui'an Equity and Hangzhou Ruihong Investment, managed by ShenZhen GTJA Investment Group and Zhuji Gaotejia Rui'an Investment managed by ShenZhen GTJA and Shanghai GTJA for CNY 45.1 million.
Nuode Asset Management Co., Ltd., GF Securities Co., Ltd. , Caitong Fund Management Co., Ltd., Shanghai Jinde Private Fund Management Co., Ltd. and Shanghai Muxin Private Fund Management Co., Ltd.... Nuode Asset Management Co., Ltd., GF…
Recent Analysts’ Ratings Changes for LB Pharmaceuticals (LBRX)
Posted by Defense World Staff on Oct 27th, 2026 Several analysts have recently updated their ratings and price targets for LB Pharmaceuticals (NASDAQ: LBRX): LB-102 is designed as a prodrug of amisulpride, an antipsychotic compound that…
LB Group's Attributable Profit Slides 43% in 2025
LB Group's attributable profit fell 43% to 1.24 billion yuan in 2025 from 2.17 billion yuan in 2024, according to a Tuesday filing with the Shenzhen bourse. Earnings per share at the titanium... LB Group Co., Ltd. LB Group's Attributable…
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Now Rated “Hold” by Wall Street Brokerages
Posted by Defense World Staff on Oct 25th, 2026 View Our Latest Stock Analysis on Lakefront Biotherapeutics American Depositary Shares LKFT stock opened at $31.65 on Friday. The company has a market capitalization of $2.09 billion, a PE…
Piper Sandler Keeps Their Hold Rating on LENZ Therapeutics (LENZ)
In a report released today, Biren Amin from Piper Sandler maintained a Hold rating on LENZ Therapeutics, with a price target of $5.00. According to TipRanks, Amin is a 3-star analyst with an average return of 0.9% and a 38.84% success…
LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Has Average Target Price of $57.40 According to Analysts
Read Our Latest Report on LB Pharmaceuticals Shares of LBRX stock opened at $38.81 on Tuesday. LB Pharmaceuticals has a one year low of $14.32 and a one year high of $50.16. The company's fifty day moving average price is $42.70 and its…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com9
- stocktitan.net5
- globenewswire.com4
- markets.businessinsider.com4
- defenseworld.net3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 37 articles, not a forecast.